Intellia.jpg
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 04, 2023 07:30 ET | Intellia Therapeutics, Inc.
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit...
Intellia.jpg
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
March 02, 2023 07:00 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia.jpg
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
May 02, 2022 16:01 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging...
Intellia.jpg
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET | Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...